JAZZ insider filings
Jazz Pharmaceuticals plc — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-10. Screen JAZZ transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 21 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 19 legs across 10 filings by 5 insiders — 171,342 shares, $41,420,682 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 39.
- Largest priced transaction: sale of 27,714 shares @ $234.91 ($6,510,357) by COZADD BRUCE C, filed 2026-11-10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| COZADD BRUCE C — Director | 4 | — | 7 legs · 86,808 sh · $20,413,317 | 6 |
| Iannone Robert — EVP, Global Head of R&D & CMO | 1 | — | 6 legs · 76,921 sh · $19,207,098 | 8 |
| GALA RENEE D — President & CEO, Director | 3 | — | 3 legs · 5,000 sh · $1,184,230 | 1 |
| Carr Patricia — SVP, Chief Accounting Officer | 1 | — | 2 legs · 1,413 sh · $326,910 | 2 |
| Patil Neena M — EVP & Chief Legal Officer | 1 | — | 1 leg · 1,200 sh · $289,128 | — |
| Henderson Mary Elizabeth — SVP, Technical Operations | 2 | — | — | 4 |
| Cook Jennifer E. — Director | 1 | — | — | 2 |
| ENRIGHT PATRICK G — Director | 1 | — | — | 2 |
| Hamill Laura — Director | 1 | — | — | 2 |
| Kennedy Patrick — Director | 1 | — | — | 2 |
+5 more insiders in the window, not shown — every filing appears in the table below.
Recent insider filings — Jazz Pharmaceuticals plc
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | COZADD BRUCE C — Director | Option exercise (M): 734 @ $136.18 · Option exercise (M): 85,766 @ $136.18 · Sale (S): 27,714 @ $234.91 · Sale (S): 10,688 @ $235.82 · Sale (S): 24,483 @ $236.84 · Sale (S): 5,923 @ $237.39 · +2 more | EDGAR |
| 2026-11-06 | 4 | Carr Patricia — SVP, Chief Accounting Officer | Option exercise (M): 1,250 @ $140.03 · Sale (S): 1,250 @ $231.37 · Sale (S): 163 @ $231.27 · Option exercise (M): 1,250 (derivative) @ $0 | EDGAR |
| 2026-11-05 | 4 | GALA RENEE D — President & CEO, Director | Sale (S): 1,000 @ $225.37 | EDGAR |
| 2026-11-04 | 4 | COZADD BRUCE C — Director | Sale (S): 6,000 @ $215.84 | EDGAR |
| 2026-10-07 | 4 | GALA RENEE D — President & CEO, Director | Sale (S): 2,000 @ $236.40 | EDGAR |
| 2026-10-05 | 4 | COZADD BRUCE C — Director | Sale (S): 6,000 @ $230.33 | EDGAR |
| 2026-09-14 | 4 | Patil Neena M — EVP & Chief Legal Officer | Sale (S): 1,200 @ $240.94 | EDGAR |
| 2026-09-10 | 4 | GALA RENEE D — President & CEO | Tax withholding (F): 1,967 @ $246.81 · Sale (S): 2,000 @ $243.03 | EDGAR |
| 2026-09-10 | 4 | Henderson Mary Elizabeth — SVP, Technical Operations | Tax withholding (F): 1,412 @ $243.03 · Tax withholding (F): 15 @ $241.20 | EDGAR |
| 2026-09-02 | 4 | Henderson Mary Elizabeth — SVP, Technical Operations | Tax withholding (F): 2,076 @ $241.39 · Tax withholding (F): 16 @ $244.64 | EDGAR |
| 2026-09-02 | 4 | Smith Mark Douglas — Director | Tax withholding (F): 14 @ $244.64 · Tax withholding (F): 1,692 @ $241.39 | EDGAR |
| 2026-09-02 | 4 | LOVE TED W — Director | Tax withholding (F): 6 @ $244.06 · Tax withholding (F): 737 @ $241.39 | EDGAR |
| 2026-09-02 | 4 | RIEDEL NORBERT G — Director | Tax withholding (F): 14 @ $244.64 · Tax withholding (F): 1,692 @ $241.39 | EDGAR |
| 2026-09-02 | 4 | Cook Jennifer E. — Director | Tax withholding (F): 14 @ $244.06 · Tax withholding (F): 1,692 @ $241.39 | EDGAR |
| 2026-09-02 | 4 | Hamill Laura — Director | Tax withholding (F): 14 @ $244.06 · Tax withholding (F): 1,692 @ $241.39 | EDGAR |
| 2026-09-02 | 4 | ENRIGHT PATRICK G — Director | Tax withholding (F): 14 @ $244.64 · Tax withholding (F): 1,692 @ $241.39 | EDGAR |
| 2026-09-02 | 4 | McSharry Heather Ann — Director | Tax withholding (F): 15 @ $244.64 · Tax withholding (F): 1,840 @ $241.39 | EDGAR |
| 2026-09-02 | 4 | Kennedy Patrick — Director | Tax withholding (F): 15 @ $244.06 · Tax withholding (F): 1,840 @ $241.39 | EDGAR |
| 2026-09-02 | 4 | Winningham Rick E — Director | Tax withholding (F): 1,692 @ $241.39 · Tax withholding (F): 14 @ $244.64 | EDGAR |
| 2026-09-02 | 4 | COZADD BRUCE C — Director | Tax withholding (F): 10 @ $244.06 · Tax withholding (F): 1,209 @ $241.39 · Sale (S): 6,000 @ $250.13 | EDGAR |
| 2026-08-31 | 4 | Iannone Robert — EVP, Global Head of R&D & CMO | Option exercise (M): 26,116 @ $113.10 · Option exercise (M): 884 @ $113.10 · Option exercise (M): 27,584 @ $137.12 · Option exercise (M): 2,916 @ $137.12 · Sale (S): 18,187 @ $247.86 · Sale (S): 11,423 @ $248.67 · +8 more | EDGAR |
| 2026-08-07 | 4 | Pearce Samantha — EVP, Chief Commercial Officer | Tax withholding (F): 780 @ $261.62 | EDGAR |
| 2026-08-07 | 4 | Winningham Rick E — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | LOVE TED W — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | Kennedy Patrick — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | Hamill Laura — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | Smith Mark Douglas — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | Cook Jennifer E. — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | Mulligan Seamus — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | ENRIGHT PATRICK G — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | McSharry Heather Ann — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | COZADD BRUCE C — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-07 | 4 | RIEDEL NORBERT G — Director | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-08-05 | 4 | COZADD BRUCE C — Director | Sale (S): 6,000 @ $252.98 | EDGAR |
| 2026-07-06 | 4 | COZADD BRUCE C — Director | Sale (S): 6,000 @ $240.47 | EDGAR |
| 2026-07-02 | 4 | Johnson Philip L — EVP & Chief Financial Officer | Tax withholding (F): 3,343 @ $237.72 | EDGAR |
| 2026-07-02 | 4 | Pearce Samantha — EVP, Chief Commercial Officer | Tax withholding (F): 2,527 @ $237.72 | EDGAR |
| 2026-07-02 | 4 | Patil Neena M — EVP & Chief Legal Officer | Tax withholding (F): 2,678 @ $237.72 | EDGAR |
| 2026-07-02 | 4 | Iannone Robert — EVP, Global Head of R&D & CMO | Tax withholding (F): 3,764 @ $237.72 | EDGAR |
| 2026-07-02 | 4 | GALA RENEE D — President & CEO | Tax withholding (F): 4,835 @ $237.72 | EDGAR |
| 2026-06-17 | 4 | Smith Mark Douglas — Director | Sale (S): 1,157 @ $230.55 | EDGAR |
| 2026-06-12 | 4 | Patil Neena M — EVP & Chief Legal Officer | Sale (S): 1,200 @ $231.83 | EDGAR |
| 2026-06-05 | 4 | GALA RENEE D — President & CEO | Gift (G): 600 @ $0 | EDGAR |
| 2026-06-03 | 4 | COZADD BRUCE C — Director | Sale (S): 6,000 @ $235.12 | EDGAR |
| 2026-06-01 | 4 | Pearce Samantha — EVP, Chief Commercial Officer | Option exercise (M): 6,907 @ $109.45 · Sale (S): 6,907 @ $235.41 · Option exercise (M): 6,907 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Patil Neena M — EVP & Chief Legal Officer | Sale (S): 1,192 @ $236.97 | EDGAR |
| 2026-06-01 | 4 | Mulligan Seamus — Director | Option exercise (M): 3,415 @ $138.08 · Option exercise (M): 3,415 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | McSharry Heather Ann — Director | Sale (S): 2,000 @ $241 | EDGAR |
| 2026-05-27 | 4 | Winningham Rick E — Director | Option exercise (M): 3,415 @ $138.08 · Sale (S): 2,741 @ $241.57 · Option exercise (M): 3,415 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | COZADD BRUCE C — Director | Sale (S): 6,000 @ $203.33 | EDGAR |
Recent 8-K events — Jazz Pharmaceuticals plc
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-26 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-10-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-09-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-08-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-25 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
GET https://api.filingpulse.io/v1/insider-trades?ticker=JAZZ returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs